R
Reija Koukakis
Researcher at Amgen
Publications - 32
Citations - 720
Reija Koukakis is an academic researcher from Amgen. The author has contributed to research in topics: Panitumumab & Colorectal cancer. The author has an hindex of 11, co-authored 32 publications receiving 592 citations.
Papers
More filters
Journal ArticleDOI
Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies.
Nele Boeckx,Reija Koukakis,K. Op de Beeck,Christian Rolfo,G. Van Camp,Salvatore Siena,Josep Tabernero,J.-Y. Douillard,Thierry André,Marc Peeters +9 more
TL;DR: RAS WT patients with left-sided tumors derive greater benefit from panitumumab-containing treatment than chemotherapy alone or combined with bevacizumab, including an overall survival advantage.
Journal ArticleDOI
Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer.
Marc Peeters,Kelly S. Oliner,Timothy J. Price,Andrés Cervantes,Alberto Sobrero,Michel Ducreux,Yevhen Hotko,Thierry André,Emily Chan,Florian Lordick,Cornelis J. A. Punt,Andrew Strickland,Gregory C. Wilson,Tudor Ciuleanu,Laslo Roman,Eric Van Cutsem,Pei He,Hua Yu,Reija Koukakis,Jan Henrik Terwey,A.S. Jung,Roger Sidhu,Scott D. Patterson +22 more
TL;DR: Findings support RAS testing for patients with mCRC and the benefit–risk of panitumumab–FOLFIRI was improved in the wild-type RAS population compared with theWild-type KRAS exon 2 population.
Journal ArticleDOI
Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer
Jean-Yves Douillard,Salvatore Siena,Marc Peeters,Reija Koukakis,Jan-Henrik Terwey,Josep Tabernero +5 more
TL;DR: Both early TS and resection were associated with improved PFS and OS and the clinical value of achieving early TS in mCRC warrants further investigation.
Journal ArticleDOI
A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
Volker Heinemann,Fernando Rivera,Bert H. O'Neil,Sebastian Stintzing,Reija Koukakis,Jan-Henrik Terwey,Jean-Yves Douillard +6 more
TL;DR: A meta-analysis supports a potential benefit for first-line EGFRI plus chemotherapy versus bevacizumab plus chemotherapy with respect to OS, ORR and ETS in patients with RAS WT mCRC.
A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer
Volker Heinemann,Fernando Rivera,Bert H. O'Neil,Sebastian Stintzing,Reija Koukakis,Jan-Henrik Terwey,Jean-Yves Douillard +6 more
TL;DR: In this paper, a study-level meta-analysis estimated the overall survival treatment effect of first-line chemotherapy plus EGFRIs or bevacizumab in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC).